Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | The future of Alzheimer’s disease: aducanumab

John Hardy • 20 Oct 2020
CONy 2020
Alzheimer’s Disease Aducanumab Antibodies
EMERGE ENGAGE

John Hardy, PhD, University College London, London, UK, discusses the aducanumab clinical trial (NCT02477800, NCT024845470), which indicated that the antibody had marginal positive effects. If this is correct, it could have significant implications for Alzheimer’s disease, although it will need to be used in conjunction with other treatments. Additionally, the incidence of Alzheimer’s disease has dropped by 20% over the last 20 years. This is attributed to the increase in better cardiac health. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.

More from John Hardy

The benefits of GWAS in understanding Alzheimer’s disease
2:00
The benefits of GWAS in understanding Alzheimer’s disease
John Hardy • 20 Oct 2020
Cross neurodegenerative disease genetic analysis: similarities and differences
2:20
Cross neurodegenerative disease genetic analysis: similarities and differences
John Hardy • 20 Oct 2020

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals